JP2004536105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536105A5 JP2004536105A5 JP2003510059A JP2003510059A JP2004536105A5 JP 2004536105 A5 JP2004536105 A5 JP 2004536105A5 JP 2003510059 A JP2003510059 A JP 2003510059A JP 2003510059 A JP2003510059 A JP 2003510059A JP 2004536105 A5 JP2004536105 A5 JP 2004536105A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- goat
- antibody
- serum composition
- goat serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283707 Capra Species 0.000 claims 15
- 210000002966 serum Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 238000004113 cell culture Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 claims 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0116151.2 | 2001-07-02 | ||
| GB0116151A GB0116151D0 (en) | 2001-07-02 | 2001-07-02 | Therapeutic agent |
| GB0128638A GB0128638D0 (en) | 2001-11-29 | 2001-11-29 | Therapeutic agent |
| GB0128638.4 | 2001-11-29 | ||
| GBGB0201896.8A GB0201896D0 (en) | 2002-01-28 | 2002-01-28 | Treatment |
| GB0201896.8 | 2002-01-28 | ||
| GB0207509A GB0207509D0 (en) | 2002-03-28 | 2002-03-28 | Therapeutic agent |
| GB0207509.1 | 2002-03-28 | ||
| PCT/GB2002/003037 WO2003004049A2 (en) | 2001-07-02 | 2002-07-02 | Use of polyclonal anti-hiv goat serum as a therapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009091136A Division JP5128539B2 (ja) | 2001-07-02 | 2009-04-03 | 治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536105A JP2004536105A (ja) | 2004-12-02 |
| JP2004536105A5 true JP2004536105A5 (https=) | 2005-09-29 |
| JP5014562B2 JP5014562B2 (ja) | 2012-08-29 |
Family
ID=27447968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003510059A Expired - Fee Related JP5014562B2 (ja) | 2001-07-02 | 2002-07-02 | 治療薬 |
| JP2009091136A Expired - Fee Related JP5128539B2 (ja) | 2001-07-02 | 2009-04-03 | 治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009091136A Expired - Fee Related JP5128539B2 (ja) | 2001-07-02 | 2009-04-03 | 治療薬 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20100291102A1 (https=) |
| EP (1) | EP1404367B1 (https=) |
| JP (2) | JP5014562B2 (https=) |
| KR (2) | KR20040030786A (https=) |
| CN (1) | CN100423776C (https=) |
| AT (1) | ATE478681T1 (https=) |
| AU (1) | AU2002317285B2 (https=) |
| BR (1) | BR0210772A (https=) |
| CA (1) | CA2452986C (https=) |
| DE (1) | DE60237447D1 (https=) |
| DK (1) | DK1404367T3 (https=) |
| EA (1) | EA013517B1 (https=) |
| HU (1) | HU228957B1 (https=) |
| IL (2) | IL159682A0 (https=) |
| MX (1) | MXPA04000147A (https=) |
| NZ (1) | NZ530393A (https=) |
| PL (1) | PL216741B1 (https=) |
| WO (1) | WO2003004049A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0201896D0 (en) * | 2002-01-28 | 2002-03-13 | Ice Biolog Ltd | Treatment |
| CA2452986C (en) * | 2001-07-02 | 2011-11-01 | Aimsco Limited | Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| AU2003202093B2 (en) * | 2001-07-02 | 2010-05-13 | Aimsco Limited | Treatment of MS with goat serum |
| SG156658A1 (en) * | 2004-04-05 | 2009-11-26 | Aimsco Ltd | Treatment of diseases |
| BRPI0513062A (pt) * | 2004-07-08 | 2008-04-22 | Aimsco Ltd | composição farmacêutica, método de estimular a produção de pomc em um paciente, usos de um peptìdeo de crf isolado e de um peptìdeo de pomc isolado, e, métodos de tratamento para uma doença, de produzir crf e de tratamento curativo, melhorador ou profilático de uma doença |
| GB0415359D0 (en) * | 2004-07-08 | 2004-08-11 | Aimsco Ltd | Medicament |
| GB0502083D0 (en) * | 2005-02-02 | 2005-03-09 | Aimsco Ltd | Bioactive compounds |
| GB0508153D0 (en) * | 2005-04-22 | 2005-06-01 | Aimsco Ltd | Therapeutic agent |
| GB0509052D0 (en) * | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
| GB0600202D0 (en) * | 2006-01-06 | 2006-02-15 | Aimsco Ltd | Treatment of HIV |
| ES2536401T3 (es) * | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| US8734852B2 (en) * | 2011-11-30 | 2014-05-27 | Manu Chaudhary | Parenteral controlled release formulations of NSAID's |
| CA2877562A1 (en) | 2012-06-25 | 2014-01-03 | Aimsco Limited | Formulation comprising crh and alpha-2 macroglobulin |
| UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
| SG11201811323XA (en) | 2017-01-31 | 2019-01-30 | Illumina Inc | Fluidic devices and methods of manufacturing the same |
| CN117538549A (zh) * | 2023-09-27 | 2024-02-09 | 上海交通大学医学院附属瑞金医院 | 一种评估血浆置换清除dsa临床疗效的预测体系 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
| JPH02237935A (ja) * | 1989-03-10 | 1990-09-20 | Bio Kagaku Kenkyusho:Kk | エイズ処置剤 |
| SK80697A3 (en) * | 1994-12-23 | 1997-12-10 | Om Lab Sa | Use of mhc-ii binding molecules |
| US6328962B2 (en) * | 1995-06-07 | 2001-12-11 | Aventis Pasteur Limited | Method for delivery of antigens to selected cells of the immune system using chimeric antibodies |
| WO1997002839A1 (en) * | 1995-07-13 | 1997-01-30 | Gkc Research, Inc. | Viral suppression, treatment and prevention of viral infections |
| WO1997039119A1 (en) * | 1996-04-15 | 1997-10-23 | Vanderbilt University | Mammalian genes involved in viral infection and tumor suppression |
| GB9619894D0 (en) * | 1996-09-24 | 1996-11-06 | Celltech Therapeutics Ltd | Pharmaceutical products |
| AU5588099A (en) * | 1998-08-28 | 2000-03-21 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| CA2270600A1 (en) * | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
| IL146566A0 (en) * | 1999-05-24 | 2002-07-25 | Sankyo Co | A pharmaceutical composition containing anti-fas antibody |
| CA2375912C (en) * | 1999-06-09 | 2014-03-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| WO2001060156A1 (en) * | 2000-02-14 | 2001-08-23 | Gary R. Davis, M.D., L.L.C. | Neutralizing antibody and immunomodulatory enhancing compositions |
| EP1156060B1 (en) * | 2000-05-12 | 2007-06-27 | GPC Biotech AG | Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells |
| EP1156062A1 (en) * | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| WO2002007760A2 (en) * | 2000-07-21 | 2002-01-31 | Ice Biologics Limited | Therapeutic agent against aids comprising anti hiv goat antibody |
| CA2452986C (en) * | 2001-07-02 | 2011-11-01 | Aimsco Limited | Use of polyclonal anti-hiv goat serum as a therapeutic agent |
-
2002
- 2002-07-02 CA CA2452986A patent/CA2452986C/en not_active Expired - Fee Related
- 2002-07-02 CN CNB028171705A patent/CN100423776C/zh not_active Expired - Fee Related
- 2002-07-02 IL IL15968202A patent/IL159682A0/xx not_active IP Right Cessation
- 2002-07-02 NZ NZ530393A patent/NZ530393A/en not_active IP Right Cessation
- 2002-07-02 BR BR0210772-4A patent/BR0210772A/pt not_active IP Right Cessation
- 2002-07-02 HU HU0401392A patent/HU228957B1/hu not_active IP Right Cessation
- 2002-07-02 KR KR10-2004-7000049A patent/KR20040030786A/ko not_active Ceased
- 2002-07-02 EP EP02745565A patent/EP1404367B1/en not_active Expired - Lifetime
- 2002-07-02 EA EA200400134A patent/EA013517B1/ru not_active IP Right Cessation
- 2002-07-02 KR KR1020097007314A patent/KR100938590B1/ko not_active Expired - Fee Related
- 2002-07-02 MX MXPA04000147A patent/MXPA04000147A/es active IP Right Grant
- 2002-07-02 WO PCT/GB2002/003037 patent/WO2003004049A2/en not_active Ceased
- 2002-07-02 DE DE60237447T patent/DE60237447D1/de not_active Expired - Lifetime
- 2002-07-02 AU AU2002317285A patent/AU2002317285B2/en not_active Ceased
- 2002-07-02 JP JP2003510059A patent/JP5014562B2/ja not_active Expired - Fee Related
- 2002-07-02 AT AT02745565T patent/ATE478681T1/de active
- 2002-07-02 PL PL367828A patent/PL216741B1/pl unknown
- 2002-07-02 DK DK02745565.8T patent/DK1404367T3/da active
- 2002-07-02 US US10/482,399 patent/US20100291102A1/en not_active Abandoned
-
2009
- 2009-04-03 JP JP2009091136A patent/JP5128539B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-09 US US13/315,830 patent/US20120100156A1/en not_active Abandoned
-
2012
- 2012-08-30 IL IL221708A patent/IL221708A/en not_active IP Right Cessation
-
2013
- 2013-02-08 US US13/763,435 patent/US20130230600A1/en not_active Abandoned
-
2015
- 2015-07-07 US US14/793,716 patent/US20160002320A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536105A5 (https=) | ||
| JP2025166059A (ja) | Ｔ制御性細胞の増殖または枯渇方法 | |
| Romagnani et al. | Role of interleukins in induction and regulation of human IgE synthesis | |
| CA2452986A1 (en) | Use of polyclonal anti-hiv goat serum as a therapeutic agent | |
| JP2012508163A5 (https=) | ||
| KR102118559B1 (ko) | 면역-관련 및 염증성 질환의 치료 | |
| Haverkamp et al. | Nontuberculous mycobacterial infections in children with inborn errors of the immune system | |
| US20170071944A1 (en) | Modulators of toll-like receptors for the treatment of hiv | |
| RU2018118575A (ru) | Способы культивирования клеток и наборы и устройство для них | |
| JP2006519228A5 (ja) | 抗原に対し霊長類を免疫寛容化する抗体の使用法 | |
| JP2017079785A5 (https=) | ||
| JP2018537962A5 (https=) | ||
| JP2013501814A5 (https=) | ||
| Baldassari et al. | Daclizumab: development, clinical trials, and practical aspects of use in multiple sclerosis | |
| RU2011116181A (ru) | Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами | |
| Hsu et al. | Cordycepin and a preparation from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model | |
| AU621830B2 (en) | Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease | |
| Teshima et al. | Regulatory T cells and IL-17-producing cells in graft-versus-host disease | |
| TW201021830A (en) | Methods to reduce B-helper T cells to treat autoimmune diseases | |
| Jeger-Madiot et al. | Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection | |
| Frantz et al. | Impact of different bone marrow cell preparations on left ventricular remodelling after experimental myocardial infarction | |
| Faustman et al. | TNFR2 agonism: basic science and promising treatment for multiple sclerosis and related diseases | |
| JP2003102471A5 (https=) | ||
| Mirowska-Guzel et al. | High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse | |
| WO2023164581A3 (en) | Fully human monoclonal antibodies against human progranulin |